Most Read

A study, conducted by The Institute of Cancer Research, London (ICR) and Paris-based cancer research institute Gustave Roussy, identified that drugs known as PARP inhibitors kill cancer cells

Vertex Pharmaceuticals and Obsidian Therapeutics have established a multi-year collaboration for the discovery of new treatments that regulate gene editing. The strategic collaboration and research and licensing agreement

Claritas Pharmaceuticals and CMAX Clinical Research have signed an agreement to conduct a Phase 1 clinical study of R-107. The clinical study is to evaluate the pharmacokinetics and

Johnson & Johnson (J&J) will resume Covid-19 vaccine roll-out in Europe following the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC), which confirmed the overall benefit-risk profile

The second indication of Sarclisa (isatuximab) for the treatment of adult patients with relapsed multiple myeloma, was approved by the European Commission (EC). This second approval of Sarclisa

The US Federal trade Commission review has granted clearance for AstraZeneca’s proposed acquisition of Alexion Pharmaceuticals, achieving an important milestone in the completion process. The clearance grant follows

GlaxoSmithKline and Vir Biotechnology have announced the European Medicines Agency (EMA) review of VIR-7831 (GSK4182136) for the early treatment of Covid-19. VIR-7831 is an investigational dual-action SARS-CoV-2 monoclonal

Bristol Myers Squibb has been granted approval by the European Commission (EC) for the use of Opdivo (nivolumab) in combination with Cabometyx (cabozantinib) to treat adults with advanced

Biopharmaceutical company SciNeuro Pharmaceuticals has signed an exclusive license agreement with Eli Lilly and Company for the development and commercialisation of alpha-synuclein targeted antibody therapies in Greater China.